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The subcutaneous implantable cardioverter deﬁbrillator (S-ICD) is a novel device now accepted in clinical
practice for treating ventricular arrhythmias. In 14 consecutive patients, S-ICD devices were placed in the
virtual space between the anterior surface of the serratus anterior muscle and the posterior surface of the
latissimus dorsi muscle. During a mean follow up of 9 months, no dislocations, infections, hematoma
formations, or skin erosions were observed. Intermuscular implantation of the S-ICD could be a reliable,
safe, and appealing alternative to the standard subcutaneous placement.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The implantable cardioverter deﬁbrillator (ICD) is a universally
accepted, evidence-based treatment for the prevention of sudden
cardiac death [1]. However, the transvenously implanted endo-
cardial lead still represents the weakest link in the ICD technology,
as it is the source of most mechanical complications and is asso-
ciated with an increased risk of bacteremia and endocarditis
infection [2–4]. Recently, a new and totally subcutaneous deﬁ-
brillator (S-ICD), that leaves the heart and vessels completely
“untouched”, has been introduced into clinical practice [5,6]. A
recent meta-analysis demonstrated that the most common
procedure-related complications for this device were limited to
the pocket: infection, hematoma, and skin erosion [7].
One shortcoming of the S-ICD is that the generator size is larger
than that of the transvenous ICD (T-ICD), as it requires a larger
battery and larger capacitors to deliver a higher energy shock
during life-threatening arrhythmias. Today, the standard implan-
ted position of the S-ICD involves a subcutaneous pocket created
over the ﬁfth intercostal space between the mid and anterior
axillary lines [8].
Patients with low body mass index, depleted fat stores, and
insufﬁcient subcutaneous tissue to adequately cover the S-ICD
device are at risk of inadequate incision site healing. In this setting,
intermuscular implantation could be an appealing alternative to a
subcutaneous pocket. In young patients, intermuscular device
placement could offer the potential advantages of a betterblished by Elsevier B.V. This is an
x þ39 035 267 4965.
).cosmetic outcome and prevention of device damage during games
and physical activities.2. Materials and methods
For surgical purposes, we can divide the target zone wall into
three planes. The ﬁrst plane is composed of skin and subcutaneous
tissue; the second is a muscular superﬁcial plane composed of the
latissimus dorsi muscle with its fascia; the third plane, a deep
muscular plane, is composed of the serratus anterior muscle and
its fascia.
The latissimus dorsi muscle is the largest muscle in the back.
The muscle originates along the T7 region of the spine and extends
to its insertion point on the humerus, speciﬁcally at the bicipital
groove. The serratus anterior muscle includes three digitations
that cover the medial wall of the axilla and penetrate deep to the
scapula to insert into its medial border. Intermuscular implanta-
tion places the S-ICD in the virtual space between the anterior
surface of the serratus anterior muscle and the posterior surface of
the latissimus dorsi muscle.
The procedures were performed in an electrophysiology
laboratory under standard sterile conditions and were carried out
during general anesthesia. After anesthesia induction, the patient’s
head and left arm were positioned to facilitate the surgery and to
promote sterility. Abduction of the left arm (60°) improved pocket
access and ensured that the generator was seated in the appro-
priate location. Slight right rotation of the head allowed sterile
draping over the manubrium and sternum and facilitated tunnel-
ing of the parasternal electrode into its upper location. Before
sterile draping, a dummy of the S-ICD and lead were secured on
the patient’s chest by adhesive plaster. The positioning of both wasopen access article under the CC BY-NC-ND license
Table 1
Characteristics of patients implanted with a subcutaneous ICD using the inter-
muscular technique (n¼14).
Male 12
Age at implant 47714 years (range 21–66)
Body mass index 2473 kg/m2
Clinical disease
Ischemic cardiomyopathy 6
Non-ischemic cardiomyopathy 3
Channelopathies 1
Hypertrophic cardiomyopathy 2
Idiopathic VF 2
Left ventricular ejection fraction indication 42714% (range 30–65%)
Primary prevention 12
Secondary prevention 2
VF¼ventricular ﬁbrillation.
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User’s Manual [8], with the pocket at the ﬁfth intercostal space
between the mid and anterior axillary lines and the lead 1–2 cm to
the left of the sternal midline. The position of the lead and S-ICD
relative to the heart silhouette was checked by ﬂuoroscopy. Finally,
the lead and S-ICD position were drawn onto the chest with a
dermographic marker pen demographic pen, as well as the inci-
sion line for the pocket creation along the chest Langer’s lines.
For the pocket, a 6 cm incision was made along the predeﬁned
Langer’s lines. Subcutaneous dissection was carried out using an
electrosurgical cutting and coagulation device, parallel to the
incision, down to the fascia overlying the latissimus dorsi muscle
(shining transparent membrane).
Intermuscular implantation places the S-ICD in the virtual
space between the latissimus dorsi and serratus anterior muscles
(Fig. 1). This area may be accessed with scissors by a blunt dis-
section, parallel to the vertical latissimus dorsi muscle ﬁbers.
When the serratus anterior is reached, it is important to recognize
the change in the ﬁber pathway, horizontal versus vertical, so that
the muscular fascia may be preserved in order to minimize
bleeding. The pocket was formed over the serratus anterior mus-
cular fascia and beneath the latissimus dorsi muscle by detaching
the ﬁbrous tissue between the muscles.
Electrode positioning was performed following the two-
incision technique described by Knops and co-workers [9]. Once
the electrode was connected to the generator and the latter was
seated in the pocket, two separate non-absorbable sutures were
inserted through the connector block suture portal and a suture
knot was tied to anchor the S-ICD to the latissimus dorsi muscle,
preventing both device migration and rotation.Fig. 1. Intermuscular implantation places the S-ICD pulse generator in the virtual
space between the anterior surface of the serratus anterior muscle and the pos-
terior surface of the latissimus dorsi muscle, over the left sixth rib between the mid
and anterior axillary lines.3. Results
An S-ICD was implanted in 14 consecutive patients using the
intermuscular pocket approach for device positioning. The character-
istics of the patient population are displayed in Table 1. All patients
underwent pre-implant screening using the only commercially avail-
able S-ICD pre-implant screening tool; all patients had at least two
vectors suitable for S-ICD sensing (three vectors in 6 patients).
The implantations, including the deﬁbrillation test (DFT), were
each performed within 60 minutes (55712min). The DFT was per-
formed after the generator had been positioned in the pocket and the
pocket closed completely. The most time-consuming step was the
closing of the wound to ensure optimal cosmetic results. No speciﬁc
bleeding issues were encountered during the procedures.
In all patients, the DFT was performed at 65 J after induction of
ventricular ﬁbrillation (VF) by 50-Hz burst stimulation. The DFT
was deemed successful if the device detected and converted the
ventricular tachycardia (VT) or VF into sinus rhythm using 65-J
standard polarity. During VF conversion testing, all 14 episodes of
induced VT or VF resulted in accurate arrhythmia detection and
termination with a shock energy r65 J and with mean time to
therapy of 15.172.2 s (range 12–19 s). After implantation, all
patients had at least two vectors suitable for S-ICD sensing based
on the S-ICD software algorithm. No signiﬁcant differences were
found in terms of vector suitability determined by the pre-implant
screening tool (ECG screening) and the S-ICD software algorithm.
During a mean follow up of 9 months (range 3–12 months), no
dislocations of either the S-ICD pulse generator or the electrode were
observed on routine chest X-rays obtained 1 day and 2 months after
implantation. One patient reported mild discomfort from the S-ICD
pocket during the ﬁrst week after implantation. This discomfort
resolved spontaneously and did not necessitate pocket revision. No
infections, hematoma formations, or skin erosions occurred during the
follow up. All device parameters were in range; in particular, no dif-
ference was found in terms of vector suitability for S-ICD sensing. All
patients were comfortable with the position and appearance of the
device (Figs. 2 and 3).
No patient experienced appropriate or inappropriate shocks. In
one patient, a short interval of T-wave oversensing caused the
device to falsely register an episode of non-sustained VT; however,
after the S-ICD was reprogrammed to a different vector, no other
over-sensing episodes were recorded.4. Discussion
In our pilot experience the intermuscular pocket approach
ensured safe and efﬁcient healing of the incision site. This may
prevent pocket-related complications, while resulting in a better
Fig. 3. Patient with intermuscular implantation of S-ICD pulse generator. The pictures show complete healing of the wound and effective concealment of the device.
Fig. 2. Postoperative chest radiography, anteroposterior view and lateral view, conﬁrming the ﬁnal position of the lead and S-ICD pulse generator.
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likely that the favorable results in terms of infections, hematoma
formation, or skin erosion will be maintained during long-term
follow up because, as shown in FDA Investigational Device
Exemption (IDE) and EFFORTLESS registry data, 40% of total
complications with the S-ICD system occur within the ﬁrst
30 days.
The footprint of the currently available S-ICD devices might
increase the risk of pocket complications, particularly in patients
who lack sufﬁcient subcutaneous tissue to cover the device ade-
quately. Moreover, the bulge created by the pulse generator could
be cosmetically disturbing, especially for young patients. In our
previous experience using the standard implantation technique,
the bulge was generally perceived as more evident.
In this pilot study we described an intermuscular pocket
approach that might be a reliable and safe alternative for S-ICD
pulse generator positioning. The technique had a 100% implanta-
tion success rate in 14 patients and no infections, hematoma for-
mations, or skin erosions occurred during the follow up. Addi-
tionally, there were no substantial procedure-related sensing
issues: only one patient had a short episode of T-wave over-
sensing, which was eliminated by reprogramming of the S-ICD to a
different vector.
Because of the absence of appropriate or inappropriate shocks in
our series of patients, we have no data about the arrhythmiatermination efﬁcacy during spontaneous VT/VF. Based on the high rate
of DFT efﬁcacy (100% at implantation), we may expect shock conver-
sion efﬁcacy during spontaneous arrhythmia events to be at least
comparable with the efﬁcacy rates reported in previous published
studies [5–7]. Moreover, the nearer to the heart the pulse generator is
placed, the more the shock vector efﬁcacy might be improved. With
the intermuscular pocket approach, the S-ICD is nearer to the heart
than it is in the conventional subcutaneous approach.
Submuscular pocket positioning for transvenous device
implantation is a widespread approach. The potential increase in
both procedural time and patient pain at the time of generator
exchange has not reduced its application. This is because the use of
the submuscular pocket has acknowledged beneﬁts for particular
patients, such as young patients and/or those with a low body
mass index. We believe the same applies to the intermuscular
pocket approach for S-ICD implantation; thus, the previously
outlined advantages make a cost–beneﬁt analysis more favorable
to intermuscular implantation than to the standard subcutaneous
approach.5. Conclusions
The intermuscular pocket approach may be a reliable and safe
alternative for S-ICD pulse generator positioning. This technique
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complications, and offer a better cosmetic effect and device con-
cealment. Of course, long-term data on a larger patient population
will be needed to establish the superiority of this technique
compared to the standard one.Conﬂict of interest
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